Nutra Pharma is providing updates on their work in utilizing their platform technology as potential countermeasures against nerve agents
Plantation, Florida, November 18, 2020 — –– Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in using their technologies as potential countermeasures against nerve agents like sarin gas and VX.
“As we have described in the past, we have long worked with neuroactive compounds in our drugs for the treatment of neurological diseases like Multiple Sclerosis,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies protect the nerves of patients with disease, our findings indicate that they may protect against – or at least mitigate the damage caused by – nerve agents that are utilized as chemical weapons; such as sarin gas and VX,” he continued. “We have continued to work with private laboratories and governmental agencies to move these projects forward and validate the technology,” he concluded.
Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that disrupt the transfer of messages to organs through the nerves. This disruption is caused by the over-stimulation of certain receptors on the surface of the neurons. These same receptors are the target of Nutra Pharma’s drugs, which may block the action of the nerve agents or minimize the damage that they may cause.
On September 22, 2020, Dr. Dale VanderPutten, CSO of Nutra Pharma was invited by the Defense Threat Reduction Agency (DTRA) to present their nerve agent countermeasure technology in a Tech Watch talk to an audience of military and civilian experts in chem/bio defense. The talk titled “A Nicotinic Acetylcholine Receptor (nAChR) Directed Organophosphate Countermeasure” was presented in a virtual internet meeting to a select expert audience invited by DTRA. The consensus of the comments and questions on the presentation supported the idea that despite past efforts, there remains an unmet need for nAChR directed defenses and that Nutra Pharma’s demonstration of human safety in the clinic and pre-clinical proof of concept deserves aggressive follow up.
“The company has very encouraging in vivo and in vitro preclinical data, a demonstrated molecular mechanism of action and a robust scientific rational for the continued commercial development of its nerve agent counter measure,” reported Dale VanderPutten, PhD, Chief Scientific Officer of Nutra Pharma. “The use of organophosphate nerve weapons (Soman, VX, Novichok, etc) is unfortunately increasing,” he continued. “The successful use of these weapons by states and terrorist groups regretfully emboldens others to use them as well. These weapons are also becoming increasingly sophisticated without any advancements in new protective agents. We believe that our nAChR directed countermeasure may provide an important tool for military and civilian defenses against these horrifying weapons,” Dr. VanderPutten concluded.
According to a BBC report, chemical weapons remain a real threat to the West. In the nine-year period since the beginning of the Syrian conflict there have been over a thousand documented uses of chemical weapons; making this issue a major topic of concern in the US department of Defense and the United Nations. Bellingcat recently reported that on October 15, 2020, the European Union imposed sanctions on six senior Russian officials and a leading Russian research institute over the alleged use of a nerve agent from the Novichok family in the poisoning of opposition leader Alexey Navalny.
As Nutra Pharma moves forward with these projects, they will provide further updates throughout the rest of 2020.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The update on the Company’s nerve agent countermeasure platform should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|Nutra Pharma Corp.